CAS number: 83919-23-7

General information about the Mometasone Furoate active pharmaceutical ingredient

Mometasone Furoate as active pharmaceutical ingredient (API) is a corticosteroid or steroid, class of glucocorticoid, with antiinflammatory, antipruritic, and vasoconstrictive properties. Mometasone Furoate is used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus. Mometasone Furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications. Inhaled Mometasone Furoate is indicated for prophylaxis of asthma. Mometasone Furoate nasal spray is used to treat and prevent the symptoms of seasonal and perennial allergic rhinitis. Applied topically as an ointment, Mometasone Furoate is indicated for symptomatic treatment of dermatitis and pruritis. Mometasone Furoate API is also used to treat skin conditions such as eczema, psoriasis, allergies, and rash. Mometasone decreases swelling, itching, and redness. Mometasone Furoate is also available as a medicine combined with antibiotics.

Axplora manufactures Mometasone Furoate API

Mometasone Furoate API is manufactured in cGMP by Axplora via chemical synthesis from early stage starting material. Mometasone Furoate API is produced by Farmabios, our EUGMP, USFDA and PMDA approved manufacturing site with legal seat in Gropello Cairoli, Italy. Farmabios’ expertise is to make and handle with steroids, niche hormones, and highly potent active pharmaceutical ingredient (HPAPI), including cytotoxic drugs. Mometasone Furoate API is commercially available as micronized grade specifically designed around various formulation requirements. Tailor-made packaging solutions are available upon request. Feel free to contact us if you n eed any additional information about Mometasone Furoate API.
  • Therapeutic area Respiratory-
  • Monograph PH.EUR.
  • Available grade Micronized
  • Regulatory documentation US DMF#
  • Produced in GRO